[3-(1H-Imidazol-1-yl)propyl](propan-2-yl)amine | 1011718-81-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [3-(1H-Imidazol-1-yl)propyl](propan-2-yl)amine
• 英文别名: 3-imidazol-1-yl-N-propan-2-ylpropan-1-amine
• CAS: 1011718-81-2
• 化学式: C₉H₁₇N₃
• mdl: MFCD10693541
• 分子量: 167.254
• InChiKey: ZHNRSWUGZCPKGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  [3-(1H-Imidazol-1-yl)propyl](propan-2-yl)amine 、 (2R)-2-((4-chloro-N-(5-chloro-2-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)phenyl)phenyl)sulfonamido)propyl (4-nitrophenyl) carbonate 以 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 C₃₁H₄₀Cl₂N₄O₆S
  参考文献：
  名称：

  Carbamate-appended N-alkylsulfonamides as inhibitors of γ-secretase

  摘要：

  The synthesis and gamma-secretase inhibition data for a series of carbamate-appended N-alkylsulfonamides are described. Carbamate 54 was found to significantly reduce brain A beta in transgenic mice. 54 was also found to possess markedly improved brain levels in transgenic mice compared to previously disclosed 1 and 2. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.102
• 作为产物：
  描述：

  1-(3-氨基丙基)咪唑 、 丙酮 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以31%的产率得到[3-(1H-Imidazol-1-yl)propyl](propan-2-yl)amine
  参考文献：
  名称：

  Carbamate-appended N-alkylsulfonamides as inhibitors of γ-secretase

  摘要：

  The synthesis and gamma-secretase inhibition data for a series of carbamate-appended N-alkylsulfonamides are described. Carbamate 54 was found to significantly reduce brain A beta in transgenic mice. 54 was also found to possess markedly improved brain levels in transgenic mice compared to previously disclosed 1 and 2. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.11.102

文献信息

• MELAMPOMAGNOLIDE B DERIVATIVES
  申请人：Janganati Venumadhav

  公开号：US20150133444A1

  公开（公告）日：2015-05-14

  The present disclosure provides derivatives of melampomagnolide B (MMB), including carbonates, carbamates, and thiocarbamates. The derivatives may be synthesized via an MMB triazole intermediate. These derivatives are useful for treating cancer in humans.

  本公开提供了槲皮素B（MMB）的衍生物，包括碳酸酯、氨基甲酸酯和硫代氨基甲酸酯。这些衍生物可以通过MMB三唑中间体合成。这些衍生物对于治疗人类癌症是有用的。
• CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
  申请人：LEHMANN-LINTZ Thorsten

  公开号：US20110217311A1

  公开（公告）日：2011-09-08

  The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2 a or Mnk2 b ) and/or variants thereof.

  本发明涉及新型噻吩并嘧啶化合物，其一般公式，包含这些化合物的药物组合物，以及它们在预防和/或治疗可通过抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）及其变体的激酶活性而影响的疾病中的治疗用途。
• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• Nitrogenous Heterocyclic Derivatives And Their Application In Drugs
  申请人：SUNSHINE LAKE PHARMA CO., LTD.

  公开号：US20150087639A1

  公开（公告）日：2015-03-26

  The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

  本发明涉及医学领域，提供了新颖的含氮杂环化合物，其制备方法及其作为药物的用途，特别是用于治疗和预防组织纤维化。还提供了包含这些含氮杂环化合物的药用组合物，以及这些组合物在治疗人类或动物组织纤维化方面的用途，特别是用于人类或动物肾间质纤维化、肾小球硬化、肝纤维化、肺纤维化、腹膜纤维化、心肌纤维化、皮肤纤维化、术后粘连、良性前列腺增生、骨骼肌纤维化、硬皮病、多发性硬化、胰腺纤维化、肝硬化、肌肉肉瘤、神经纤维瘤、肺间质纤维化、糖尿病肾病、阿尔茨海默病或血管纤维化。
• SMALL MOLECULE ENTEROVIRUS INHIBITORS AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20210244721A1

  公开（公告）日：2021-08-12

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quinoline (or similar) structure which function as antagonists of androgen receptor activity, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer) and other conditions characterized with androgen receptor activity and/or androgen receptor expression.

  这项发明属于药物化学领域。具体而言，该发明涉及一类新型的小分子，其具有喹啉（或类似）结构，可作为雄激素受体活性拮抗剂，并且可用作治疗癌症（例如去势抵抗性前列腺癌）和其他与雄激素受体活性和/或雄激素受体表达有关的疾病的治疗药物。